Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Assets (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Assets for 3 consecutive years, with $177.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets changed N/A to $177.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $177.5 million, a N/A change, with the full-year FY2024 number at $180.8 million, down 41.29% from a year prior.
  • Assets was $177.5 million for Q3 2025 at Inhibrx Biosciences, down from $212.1 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $307.9 million in Q4 2023 to a low of $177.5 million in Q3 2025.
  • A 3-year average of $227.3 million and a median of $212.1 million in 2025 define the central range for Assets.
  • Peak YoY movement for Assets: plummeted 41.29% in 2024, then dropped 17.92% in 2025.
  • Inhibrx Biosciences' Assets stood at $307.9 million in 2023, then plummeted by 41.29% to $180.8 million in 2024, then fell by 1.82% to $177.5 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Assets are $177.5 million (Q3 2025), $212.1 million (Q2 2025), and $180.8 million (Q4 2024).